DALLAS--(BUSINESS WIRE)--Cerebain Biotech Corp. (“Cerebain” or “the Company”), a subsidiary of Discount Dental Materials, Inc. (OTCBB: DDOO), announced that medical device product development company, Sonos Models, Inc. (“Sonos”), has provided additional photo of the first prototype of the Company’s medical device solution for the treatment of Alzheimer’s disease utilizing the Omentum.
The new photo of the medical device prototype now depicts the electrodes which are intended to provide continuous Omentum stimulation, a novel approach to the treatment for patients suffering from Alzheimer’s disease.
About Discount Dental Materials, Inc.
Discount Dental Materials, Inc. was incorporated in Nevada on December 17, 2007. The Company’s business will revolve around the discovery of products for the treatment of Alzheimer’s disease utilizing Omentum. The Company’s approach will consider both a medical device solution as well as a synthetic drug solution. The Company’s operations will be conducted through its wholly-owned subsidiary, Cerebain Biotech Corp. For more information about Discount Dental and Cerebain Biotech, please visit the Company’s website at www.cerebain.com and www.otcmarkets.com, under the ticker symbol “DDOO,” to view the Company’s public filings and stock quote.
This news release contains certain "forward- looking statements." Forward-looking statements are based on current expectations and assumptions and are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, and many of which are beyond the Company's control. The forward-looking statements are also identified through the use of words "believe," enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict" "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from these forward-looking statements as a result of a number of risk factors detailed in the Company's reports filed with OTC Markets. Given these risks and uncertainties, investors are cautioned not to place undue reliance on such forward-looking statements and no assurances can be given that such statements will be achieved.